Gallery
- Karnataka rain fury: Photos of flooded streets, uprooted treesCannes 2022: Deepika Padukone stuns at the French Riviera in Sabyasachi outfitRanbir Kapoor And Alia Bhatt's Wedding Pics - Sealed With A KissOscars 2022: Every Academy Award WinnerShane Warne (1969-2022): Australian cricket legend's life in picturesPhotos: What Russia's invasion of Ukraine looks like on the groundLata Mangeshkar (1929-2022): A pictorial tribute to the 'Nightingale of India'PM Modi unveils 216-feet tall Statue of Equality in Hyderabad (PHOTOS)Wedding pics: Mouni Roy marries Suraj Nambiar in South Indian ceremony73rd Republic Day Parade 2022 - In Pictures
World no. 1 Serbian tennis great Novak Djokovic was named Laureus World Sportsman of the Y
- Asian Games medallist Jyothi Yarraji to train in Spain ahead of Paris Olympics
- Lione Messi said Retirement not on my mind
- Indian Wells: Alcaraz, Swiatek win titles
- African footballer chased and thrashed away in Kerala; reports
- Hockey India announce core probable group for men's national camp in Bhubaneswar
New study show immunity drops quickly in mild COVID-19 cases Last Updated : 22 Jul 2020 08:31:16 AM IST COVID-19 antibodies A study shows that in people with mild COVID-19 cases, their antibodies against the coronavirus drop sharply over the first three months after infection.
A research team at the University of California, Los Angeles, did an in-depth study of 34 people who had recovered from mild COVID-19 infections. They tested their blood two or three times over three months, Xinhua news agency reported on Tuesday.The researchers found a rapid drop in antibodies - the immune system proteins that help stop viruses from infecting cells in the body. On average, the antibody levels fell by half every 73 days, according to the study published in The New England Journal of Medicine.The findings raise concern that humoral immunity against SARS-CoV-2 may not be long lasting in persons with mild illness, who compose the majority of persons with COVID-19, said the study.Further studies will be needed to define a quantitative protection threshold and rate of decline of antiviral antibodies beyond 90 days, according to the study.IANS Washington For Latest Updates Please-
Join us on
Follow us on
172.31.16.186